{"id":"https://openalex.org/W1972097076","doi":"https://doi.org/10.5414/cp201806","title":"Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation","display_name":"Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation","alternate_titles":[],"publication_year":2013,"publication_date":"2013-04-25","ids":{"openalex":"https://openalex.org/W1972097076","doi":"https://doi.org/10.5414/cp201806","mag":"1972097076","pmid":"https://pubmed.ncbi.nlm.nih.gov/23611572"},"language":"en","primary_location":{"id":"doi:10.5414/cp201806","doi":"https://doi.org/10.5414/cp201806","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp201806","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1972097076"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021505955","display_name":"Marcelo M. Gutierrez","orcid":"https://orcid.org/0000-0002-6465-5773","observed_orcids":["https://orcid.org/0000-0002-6465-5773"]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Marcelo M. Gutierrez","raw_affiliation_strings":["Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. jasper.dingemanse@actelion.com","Actelion Pharmaceuticals Ltd, Allschwil,Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. jasper.dingemanse@actelion.com","institution_ids":["https://openalex.org/I95056601"]},{"raw_affiliation_string":"Actelion Pharmaceuticals Ltd, Allschwil,Switzerland","institution_ids":["https://openalex.org/I95056601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103501686","display_name":"Laurent B. Nicolas","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Laurent B. Nicolas","raw_affiliation_strings":["Actelion (Switzerland), Allschwil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion (Switzerland), Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072900620","display_name":"Yves Donazzolo","orcid":"https://orcid.org/0009-0002-4314-607X","observed_orcids":["https://orcid.org/0009-0002-4314-607X"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yves Donazzolo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5058093690","display_name":"Jasper Dingemanse","orcid":"https://orcid.org/0000-0002-4083-5817","observed_orcids":["https://orcid.org/0000-0002-4083-5817"]},"institutions":[{"id":"https://openalex.org/I95056601","display_name":"Actelion (Switzerland)","ror":"https://ror.org/001yedb91","country_code":"CH","type":"company","lineage":["https://openalex.org/I95056601"]}],"countries":["CH"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jasper Dingemanse","raw_affiliation_strings":["Actelion (Switzerland), Allschwil, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Actelion (Switzerland), Allschwil, Switzerland","institution_ids":["https://openalex.org/I95056601"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.6015,"has_fulltext":false,"cited_by_count":14,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.82122883,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":95},"biblio":{"volume":"51","issue":"06","first_page":"529","last_page":"536"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.9771000146865845,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.9771000146865845,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10728","display_name":"Pulmonary Hypertension Research and Treatments","score":0.01269999984651804,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11235","display_name":"Statistical Methods in Clinical Trials","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/2613","display_name":"Statistics and Probability"},"field":{"id":"https://openalex.org/fields/26","display_name":"Mathematics"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bosentan","display_name":"bosentan","score":1.0},{"id":"https://openalex.org/keywords/pediatric-drug-formulation","display_name":"pediatric formulations","score":0.9380000233650208},{"id":"https://openalex.org/keywords/relative-bioavailability","display_name":"relative bioavailability","score":0.8019999861717224},{"id":"https://openalex.org/keywords/bioequivalence","display_name":"bioequivalence","score":0.8700000047683716},{"id":"https://openalex.org/keywords/pulmonary-arterial-hypertension","display_name":"pulmonary arterial hypertension","score":0.828000009059906},{"id":"https://openalex.org/keywords/endothelin-receptor-antagonists","display_name":"endothelin receptor antagonists","score":0.8659999966621399},{"id":"https://openalex.org/keywords/bioactive-metabolites","display_name":"bioactive metabolites","score":0.7760000228881836},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.765999972820282},{"id":"https://openalex.org/keywords/dispersible-tablets","display_name":"dispersible tablets","score":0.6909999847412109},{"id":"https://openalex.org/keywords/formulation-comparison","display_name":"formulation comparison","score":0.49900001287460327}],"concepts":[{"id":"https://openalex.org/C2781109936","wikidata":"https://www.wikidata.org/wiki/Q419769","display_name":"Bosentan","level":4,"score":0.9807611703872681},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.8184641599655151},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.7740646004676819},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7255352735519409},{"id":"https://openalex.org/C42404028","wikidata":"https://www.wikidata.org/wiki/Q864940","display_name":"Bioequivalence","level":3,"score":0.7084466218948364},{"id":"https://openalex.org/C2776345702","wikidata":"https://www.wikidata.org/wiki/Q390709","display_name":"Endothelin receptor antagonist","level":4,"score":0.6960127949714661},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.6803930997848511},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.6533416509628296},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.643840491771698},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.6134041547775269},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.609269917011261},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.5452743768692017},{"id":"https://openalex.org/C2777056448","wikidata":"https://www.wikidata.org/wiki/Q285166","display_name":"Oral administration","level":2,"score":0.41402238607406616},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.33317071199417114},{"id":"https://openalex.org/C144980905","wikidata":"https://www.wikidata.org/wiki/Q24721308","display_name":"Endothelin receptor","level":3,"score":0.28995662927627563},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09120577573776245},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.06878513097763062},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000077300","descriptor_name":"Bosentan","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002626","descriptor_name":"Chemistry, Pharmaceutical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006976","descriptor_name":"Hypertension, Pulmonary","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011237","descriptor_name":"Predictive Value of Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D013449","descriptor_name":"Sulfonamides","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065128","descriptor_name":"Endothelin Receptor Antagonists","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.5414/cp201806","doi":"https://doi.org/10.5414/cp201806","is_oa":false,"landing_page_url":"https://doi.org/10.5414/cp201806","pdf_url":null,"source":{"id":"https://openalex.org/S166536441","display_name":"International Journal of Clinical Pharmacology and Therapeutics","issn_l":"0946-1965","issn":["0946-1965"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","medline","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310313675","host_organization_name":"Dustri-Verlag","host_organization_lineage":["https://openalex.org/P4310313675"],"host_organization_lineage_names":["Dustri-Verlag"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Int. Journal of Clinical Pharmacology and Therapeutics","raw_type":"journal-article"},{"id":"pmid:23611572","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23611572","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"International journal of clinical pharmacology and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2118901354","https://openalex.org/W2067115616","https://openalex.org/W2160357354","https://openalex.org/W2572716593","https://openalex.org/W2588690000","https://openalex.org/W2010511169","https://openalex.org/W2042356209","https://openalex.org/W4406597591","https://openalex.org/W2090659780","https://openalex.org/W2396724280"],"abstract_inverted_index":{"WHAT":[0,198],"IS":[1,199],"KNOWN:":[2],"Bosentan":[3],"is":[4,21],"a":[5,29,128],"dual":[6],"endothelin":[7],"receptor":[8],"antagonist":[9],"approved":[10],"for":[11,153,186],"the":[12,37,49,54,66,71,78,144,149,163,187,204,209,221,235],"treatment":[13,147],"of":[14,40,48,65,73,80,104,107,120,157,173,208,213,232,237],"pulmonary":[15],"arterial":[16],"hypertension":[17],"(PAH).":[18],"Since":[19],"bosentan":[20,41,108,133,158,238],"frequently":[22],"used":[23],"to":[24,60,69,99,131],"treat":[25],"pediatric":[26,30,52,118,150],"PAH":[27],"patients,":[28],"formulation":[31,165,233],"was":[32,242],"developed.":[33],"AIM:":[34],"To":[35],"evaluate":[36],"pharmacokinetic":[38],"properties":[39],"and":[42,77,113,134,142,155,177,215,239],"its":[43,135],"active":[44,189],"metabolite,":[45],"Ro":[46,191,240],"48-5033,":[47],"quadrisected,":[50],"dispersible":[51],"vs.":[53],"adult":[55,111,164],"tablet":[56,112],"after":[57],"single-dose":[58],"administration":[59],"healthy":[61],"subjects.":[62],"Secondary":[63],"objectives":[64],"study":[67],"were":[68,97,125,140,159,184,195,217,246],"compare":[70],"pharmacokinetics":[72,236],"two":[74],"inactive":[75],"metabolites":[76],"safety":[79],"both":[81],"formulations.":[82],"MATERIALS":[83],"AND":[84,201],"METHODS:":[85],"In":[86],"this":[87],"open-label,":[88],"two-way":[89],"crossover":[90],"study,":[91],"subjects":[92,139],"(20":[93],"-":[94,226],"43":[95],"years)":[96],"randomized":[98],"receive":[100],"single":[101],"oral":[102],"doses":[103],"62.5":[105],"mg":[106,115],"as":[109,116],"1":[110],"64":[114],"2":[117],"tablets":[119],"32":[121],"mg.":[122],"Blood":[123],"samples":[124],"drawn":[126],"over":[127],"48-hour":[129],"period":[130],"measure":[132],"metabolites.":[136],"RESULTS:":[137],"16":[138],"enrolled":[141],"completed":[143],"study.":[145],"Following":[146],"with":[148,162,166],"formulation,":[151],"values":[152],"Cmax":[154,214],"AUC0-\u221e":[156,216],"lower":[160],"than":[161],"geometric":[167,210],"mean":[168,211],"ratios":[169,212],"(90%":[170],"confidence":[171,206],"interval)":[172],"0.82":[174],"(0.65,":[175],"1.04)":[176],"0.87":[178],"(0.78,":[179],"0.97),":[180],"respectively.":[181],"Similar":[182],"results":[183],"obtained":[185],"primary":[188],"metabolite":[190],"48-5033.":[192],"Both":[193,244],"treatments":[194],"well":[196,247],"tolerated.":[197,248],"NEW":[200],"CONCLUSION:":[202],"Although":[203],"90%":[205],"intervals":[207],"not":[218],"entirely":[219],"within":[220],"conventional":[222],"bioequivalence":[223],"range":[224],"(0.80":[225],"1.25),":[227],"no":[228],"clinically":[229],"relevant":[230],"effect":[231],"on":[234],"48-5033":[241],"detected.":[243],"formulations":[245]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1972097076","counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":2},{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
